Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Keros Therapeutics, Inc.NASDAQ: KROS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $403K rose 17.2% year over year, behind the +21.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 34.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.2% toward the trailing-twelve-month pace of +21.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.51M USD
- Year-over-year change
- +22.8%
- 4-year CAGR
- +41.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.51M | +22.8% |
| FY2024 | 2024-12-31 | 1.23M | +50.8% |
| FY2023 | 2023-12-31 | 815K | +20.9% |
| FY2022 | 2022-12-31 | 674K | +78.3% |
| FY2021 | 2021-12-31 | 378K | — |
Depreciation & Amortization vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 depreciation & amortization of $1.57M is the 6th highest of the 10 companies compared; the peer median is $1.71M.
- Its year-over-year change of +21.0% is the 4th highest of 10, against a peer median of +11.1%.
- Depreciation & amortization amounts to 4.7% of revenue for KROS, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $11.4M | -12.6% | -3.4% | 620.8% | |
| LTM Mar 2026 | $3.08M | +50.1% | +151.3% | — | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $1.71M | +16.6% | -8.4% | 1.3% |
| LTM Mar 2026 | $1.57M | +21.0% | +30.8% | 4.7% | |
| LTM Mar 2026 | $1.24M | -26.3% | -17.4% | 3.5% | |
| LTM Mar 2026 | $997K | +3223.3% | +83.4% | 2.0% | |
| LTM Mar 2026 | $481K | +11.1% | +11.1% | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding KROS) | $1.71M | +11.1% | +6.5% | 2.8% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.1M | 0 | 151K | 3.55M | 244.06M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.51M |
| Gross Profit | 20.1M | 0 | 151K | 3.55M | 242.55M |
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 99.4% |
| Research & Development | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
| Selling, General & Admin | 21.33M | 27.53M | 34.83M | 40.75M | 46.85M |
| Operating Expenses | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| EBITDA | (56.35M) | (104M) | (152.18M) | (185.82M) | 93.41M |
| EBITDA Margin | -280.4% | — | -100779.5% | -5234.5% | 38.3% |
| Operating Income | (56.37M) | (114.79M) | (169.94M) | (210.83M) | 70.62M |
| Operating Margin | -280.5% | — | -112543.7% | -5939.0% | 28.9% |
| Interest Income | 0 | 1K | 0 | 0 | 0 |
| Interest Expense | 4K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (360K) | 10.11M | 16.95M | 23.78M | 21.27M |
| Income Before Tax | (56.73M) | (104.68M) | (152.99M) | (187.05M) | 91.9M |
| Pre-Tax Margin | -282.3% | — | -101319.2% | -5269.1% | 37.7% |
| Income Tax Expense | 2.01M | 0 | 0 | 300K | 4.88M |
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Net Margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (Basic) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 |
| EPS (Diluted) | (2.52) | (4.15) | (5.20) | (5.00) | 2.30 |
| Weighted Avg Shares | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M |
| Weighted Avg Shares (Diluted) | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.